Drug guidance
Momelotinib for treating myelofibrosis in patients with moderate to severe anaemia
Condition
Blood and Immune System
Cancer
6 February 2026
-
Published on 16 Sep 2025
Last Updated on 06 Feb 2026
Guidance Recommendations
The Ministry of Health’s Drug Advisory Committee has recommended:
Momelotinib 100 mg, 150 mg and 200 mg tabletsfor treating myelofibrosis-related splenomegaly or symptoms in patients with moderate to severe anaemia.
Funding status
Momelotinib 100 mg, 150 mg and 200 mg tablets are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 April 2026.
Clinical indication, subsidy class and MediShield Life claim limit for momelotinib are provided in the Annex.